(Q35996488)

11 August 2017

1 reference

title

Management of androgen-independent prostate cancer (English)

1 reference

11 August 2017

1 reference

Michael Diaz

1

1 reference

11 August 2017

Stephen G Patterson

series ordinal

2

1 reference

11 August 2017

publication date

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

11

1 reference

11 August 2017

issue

6

1 reference

11 August 2017

page(s)

364-373

1 reference

11 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Assessment of hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Hormone-refractory (D3) prostate cancer: refining the concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Secondary hormonal therapies in the treatment of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo .

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Phase II study of vinorelbine in patients with androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100604

10.1177/107327480401100604

21 January 2018

Identifiers

DOI

0 references

1 reference